timothy sykes logo
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment Thumbnail
ADD US ONG Google News

Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment

ELLIS HOBBS•UPDATED MAR. 21, 2026, 11:04 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Dermata Therapeutics Inc.’s stocks have been trading up by 9.92 percent, driven by promising FDA designations.

Candlestick Chart

Weekly Update Mar 16 – Mar 20, 2026: On Saturday, March 21, 2026 Dermata Therapeutics Inc. stock [NASDAQ: DRMA] is trending up by 9.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

  1. Market Position & Fundamentals: Dermata Therapeutics, Inc. (DRMA) maintains a high-risk financial posture due to significant losses that overshadow its market position. Key financials reveal a pretax profit margin of -633.2%, underlining its ongoing operational deficits. Despite zero debt, the company struggles with a negative cash flow of -3.28 and a BVPS of 1.4. The current ratio of 4.6 indicates sufficient liquidity, yet the return on assets and equity, both deeply negative (-110.8% and -67.52% respectively), highlight inefficiencies in its capital deployment. Dermata’s enterprise value of -$524,526 suggests a market perception of declining worth, necessitating strategic pivots to improve investor confidence and financial sustainability.

  2. Technical Analysis & Trading Strategy: Analysis of Dermata’s recent weekly price action indicates a volatile trading pattern, with substantial fluctuations. This is highlighted by a climb from $1.19 to a high of $1.73 before closing at $1.63, and a subsequent drop to $1.33. Dominant bearish pressure is evident as the stock faces resistance near $1.73. Current price action suggests a short-term bearish trend, with volume patterns offering minimal support to halt downward momentum. A prudent trading strategy involves short-selling around the $1.63-$1.73 resistance range, targeting a decline towards $1.26, considering no substantial support exists above this price level.

  3. Catalysts & Outlook: Recent strategic developments, notably the shift towards a direct-to-consumer model with the launch of Tome Skincare, introduce potential growth catalysts for Dermata. The appointment of Kyra Peckaitis as VP of Marketing is pivotal, given her mandate to spearhead this transition aimed at seizing share in the “skintech” space. However, with planned launches deferred until mid-2026, immediate financial relief is unlikely. Relative to sector benchmarks in Biotechnology & Life Sciences, expectations remain tempered due to Dermata’s slow revenue growth rate and undercapitalization. Resistance is anticipated near $1.73, with support at $1.26. Although the shift is strategically sound, execution risks persist, warranting a cautious stance.

Quick Financial Overview

Dermata Therapeutics, amidst its strategic realignment, displays fluctuating stock movements as it transitions to the skincare sector. Recent trading data reveals a dynamic picture: a significant peak with a high of $1.73 on March 19, before correcting to close at $1.33 on March 20. The stock’s volatility underlines market participants’ mixed sentiment about this bold shift.

Key financial ratios depict challenges. The pretax profit margin stands at an alarming -633.2, reflecting ongoing operational difficulties. The company’s enterprise value seems negative, at -$524,526, suggesting further strategic review may be required to align financial stability with growth plans.

More Breaking News

Financial statements show Dermata grappling with negative cash flows and a harsh net income figure of -$1,691,989, highlighting the financial pressures faced during this extensive strategic pivot. The firm’s healthy current ratio of 4.6 and quick ratio of 4.2, however, suggest adequate liquid resources to withstand near-term financial challenges. This resilience will be crucial as Dermata attempts to secure its footing in a new market.

Conclusion

In conclusion, Dermata Therapeutics is embarking on a transformative journey, pivoting unmistakably toward the burgeoning direct-to-consumer skincare market. With Kyra Peckaitis at the helm of Tome Skincare’s launch, the company aligns itself with evolving market dynamics and consumer demand. Navigating this transition demands adept financial management to reconcile initial losses with potential long-term gains. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This trading wisdom underscores Dermata’s approach to balancing risk and reward. Market participants are poised to watch how Dermata capitalizes on this pivotal moment, balancing innovation with proven commercial strategies.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading DRMA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”